Amneal Pharmaceuticals AMRX shares are trading higher on Friday after the company reported the launch of Generic Fluphenazine following Abbreviated New Drug Application approval by the FDA.
Amneal Pharmaceuticals is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products.
Amneal Pharmaceuticals shares were trading up 5.73% at $4.61 at the time of publication on Friday. The stock has a 52-week high of $5.79 and a 52-week low of $2.27.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
